TheraRadar
Data updated: May 26, 2026

HECTOROL (doxercalciferol)

Trial Activity: Declining
Renal Approved 1999-06-09

Development Insights

Mariana Markell conducting 1 trials (20%)
8 indications explored (Moderate)
chronic kidney disease (3 trials)
hyperparathyroidism, secondary (2 trials)
kidney transplantation (1 trials)
4
Indications
--
Phase 3 Trials
26
Years on Market

Details

Status
Discontinued
First Approved
1999-06-09
Patent Cliff
2028

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INJECTION, ORAL
Dosage Forms
INJECTABLE, CAPSULE

Companies

Active Ingredient: DOXERCALCIFEROL

HECTOROL Approval History

2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
90 FDA actions from 1999 to 2025 · 2 indication expansions
Jun 2025 SUPPL
Efficacy
Sep 2022 SUPPL
Label · Labeling
Nov 2018 SUPPL
Label · Labeling

What HECTOROL Treats

4 FDA approvals

Originally approved for its first indication in 1999 . Covers 4 distinct patient populations.

  • Other (4)
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT00889629 08-080 Ph 4 completed Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients
NCT02282813 results posted CTAP101-CL-3003 Ph 3 completed Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
NCT00646282 PAD results posted IRB00006614 Ph 4 terminated Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients
NCT00792857 CTAP201-CL-1007 Ph 1 completed Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
NCT00601107 results posted HECTPS02507 Ph 2 completed A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

HECTOROL FDA Label Details

HECTOROL Patents & Exclusivity

Exclusivity: Jun 2028

Exclusivity

M-14 Until Jun 2028
M-14 Until Jun 2028
M-14 Until Jun 2028
M-14 Until Jun 2028
M-14 Until Jun 2028
M-14 Until Jun 2028
M-14 Until Jun 2028
M-14 Until Jun 2028
M-14 Until Jun 2028
Source: FDA Orange Book

Track HECTOROL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment